In the world of modern healthcare, there’s a new term that’s creating waves: Diabesity. Coined to capture the dual epidemic of diabetes and obesity, diabesity highlights how these two chronic conditions often go hand-in-hand—and how addressing them together may hold the key to better health outcomes. Diabesity: A Global Health Crisis Let’s break it down: … Read more
Retatrutide is a promising experimental weight loss drug under development by Eli Lilly. Known as the “Triple G” drug, it mimics three hormones (GLP-1, GIP, and glucagon) to promote significant weight loss. Early studies show it outperforms existing FDA-approved drugs like Ozempic, helping patients lose up to 22% of their weight in 48 weeks. Retatrutide … Read more
GLORY-1 is an innovative investigational therapy in the field of metabolic health, designed as a dual receptor agonist targeting both glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptors. Developed by Innovent Biologics, GLORY-1—also known by its research name, Mazdutide—aims to deliver superior efficacy for weight loss and metabolic improvements by combining the actions of these two … Read more
A landmark Phase 3 clinical study of mazdutide, the world’s first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, has been published in The New England Journal of Medicine (NEJM), signaling a pivotal advancement in the fight against obesity. The trial, known as GLORY-1, demonstrates the remarkable efficacy and safety of mazdutide in Chinese adults with … Read more
Obesity isn’t just about weight—it’s a complex medical condition linked to serious health risks like diabetes, heart disease, and cancer. But how do you know if you (or a loved one) are at risk? Here are 7 key signs of obesity to watch for: 1. High BMI (Body Mass Index) – But It’s Not Perfect ⚠️ Limitation: BMI doesn’t account … Read more
The global obesity drug market is experiencing significant growth, with projections exceeding $150 billion annually in the coming decade. This surge is driven by the development and success of GLP-1 receptor agonists and related therapies. Here’s an analysis of key publicly traded companies leading this sector: 1. Eli Lilly & Co. (NYSE: LLY) 2. Novo … Read more
Key Findings at a Glance The Study: How Weight-Loss Drugs Stack Up Against Surgery A landmark Israeli study (presented at the European Congress on Obesity 2025 and published in The Lancet’s eClinicalMedicine) analyzed 6,000 adults with obesity but no prior cancer. Two Groups Compared: Surprising Results Lead author Prof. Dror Dicker (Israel):“Newer GLP-1 drugs like Mounjaro may be even more powerful … Read more
